Diroximel Fumarate: A Comprehensive Overview

Overview:

Relapsing types of multiple sclerosis (MS) are treated with a medicine called Diroximel fumarate. It functions as an anti-inflammatory and immunosuppressive medication. Gastrointestinal issues and flushing are the most frequent side effects. In October 2019, the European Medical Agency (EMA) and the United States Food and Drug Administration (FDA) authorized the medicinal use of Diroximel fumarate. This approval came about in November 2021.

Drug group:

The drug Diroximel fumarate is a member of the fumarate drug class. A class of substances known as fumarates has been investigated for possible use in the treatment of autoimmune diseases, including multiple sclerosis (MS). Diroximel fumarate is another drug that is frequently used in the treatment of multiple sclerosis. It belongs to the fumarate family.

Available doses and dosage forms:

Patients can choose from various dosages and formulations of Diroximel fumarate to meet their specific needs. Usually, tablets are provided for the drug so that it may be easily taken orally. The available dosages may vary, and medical professionals select the most suitable dosage based on the patient's age, the severity of the illness, and overall health.

• Strengths of tablets:

Oral pills: Common pill strengths for Diroximel fumarate include 231 milligrams (mg) and 462 mg.

• Administration and dosage:

The recommended dosage of Diroximel fumarate involves taking it twice a day, which healthcare professionals determine according to the specific needs of each patient. By following this dosage regimen, healthcare providers enhance patient adherence to their medications and enable medicines to fit more smoothly into the daily activities of their treatment of multiple sclerosis.

For Patients:

What Are the Uses of Diroximel Fumarate?

Diroximel fumarate is primarily utilized as a treatment for particular diseases. These are its primary applications:

• Multiple sclerosis (MS): First-line therapies for relapsing forms of the disease are treated with diroximel fumarate. It ameliorates the disease’s severity and contributes to the decrease in the number of relapses.

• Psoriasis: Owing to the immunomodulating effects of diroximel fumarate, as with other fumarates, the compound is likely to have therapeutic efficacy in psoriasis.

• Chronic inflammatory illnesses: Additional study is necessary; however, since it is an anti-inflammatory agent, it may be useful for those conditions that involve low-grade inflammation.

• Combination therapy: By enhancing the treatment of several diseases, such as multiple sclerosis, diroximel fumarate can also be taken in combination with other medications.

Why Is How Diroximel Fumarate Prescribed and How Does It Work?

An oral disease-modifying medication (DMT) called Diroximel fumarate is used to treat relapse types of multiple sclerosis. It is a member of the Diroximel fumarate drug class, which also contains fumarate. Although the precise mechanism of action of Diroximel fumarate in managing multiple sclerosis remains unclear, it is thought to have anti-inflammatory and neuroprotective properties.

The medicine is a prodrug of monomethyl fumarate; when taken orally, the body metabolizes it to produce the active ingredient. Monomethyl fumarate is believed to regulate the immune system, lowering central nervous system inflammation. Diroximel fumarate, therefore, offers a therapeutic advantage to MS patients by slowing down the disease's course and reducing the frequency of relapses.

What Is the Dosage of Diroximel Fumarate?

For the first seven days, take one capsule twice daily; then, take two capsules twice daily. Encourage patients to take Diroximel fumarate precisely as directed. Tell patients to take whole Diroximel fumarate pills without breaking them down. Remind patients not to chew, crush, or break the capsules and not to sprinkle their contents on meals.

Advise patients not to consume a high-fat, high-calorie meal or snack for at least 2 hours before taking Diroximel fumarate. If consumed with food, the meal or snack should include no more than 30 grams of fat and no more than 1.05 ounces of fat. Patients should be advised not to take Diroximel fumarate and alcohol at the same time.

How Effective Is Diroximel Fumarate?

Diroximel fumarate has been shown in clinical studies to be beneficial in treating relapse types of multiple sclerosis. According to studies, Diroximel fumarate considerably lowers the annualized recurrence rate and slows the course of impairment. With typical side effects, including flushing, gastrointestinal discomfort, and moderate reductions in white blood cell counts, the safety profile of Diroximel fumarate also seems favorable.

Diroximel fumarate's efficacy varies from patient to patient. The total efficacy of Diroximel fumarate in treating multiple sclerosis (MS) can be influenced by several factors, including compliance with the recommended treatment regimen, the unique characteristics of each patient's disease, and any other concurrent medical conditions.

What Are the Things to Inform the Doctor Before Taking the Drug?

• Suffer from any liver issues.

• Suffer from renal issues.

• Have an infection or low white blood cell levels.

• Whether Diroximel fumarate will affect the unborn child is unknown. Avoid using the drug while expecting a child or already having one.

• Suppose the patient is nursing or intends to start nursing. The possibility of Diroximel fumarate entering the breast milk is unknown. When taking Diroximel fumarate, consult the healthcare professional about how to feed your infant.

• Inform the physician about all medications, including over-the-counter and prescription drugs, vitamins, and herbal supplements.

How to Use Diroximel Fumarate Medication?

Adhere to the doctor's prescription for Diroximel fumarate precisely. The pill should be swallowed whole with water; do not chew, break, or crush it. For optimal treatment outcomes, continuously adhere to the prescribed dose regimen.

What Should I Watch While Using This Medicine?

• Gastrointestinal side effects: Symptoms include nausea, diarrhea, and abdominal pain. How to treat it: drink water; consider adjusting your diet.

• Liver function: Follow-up on liver enzymes should be frequent. Fatigue, jaundice, and yellowish coloration of urine and abdominal pain.

• Infections: Symptoms include fever, chills, or a persistent cough.

• Allergic reactions: Hives, sores, and swollen reactions or an even worse dizzy effect. If these occur, seek medical aid.

• Neurological manifestations: Inform your healthcare provider if you experience new symptoms or if your existing symptoms worsen, such as vision problems or weakness.

• Pregnant and lactating: Never take any chances; always consult with your doctor about the risks first.

What Are the Side Effects of Diroximel Fumarate?

1. An allergic response:

• Welts.

• Hives.

• Face, lip, mouth, or tongue swelling.

• Trouble breathing.

2. Progressive multifocal leukoencephalopathy (PML):

It is an uncommon brain illness that often results in weeks or months of severe impairment or death.

• Deteriorating weakness on one side of the body.

• Clumsiness in the arms or legs.

• Visual issues.

• Cognitive and memory impairments.

• Disorientation changes

• Personality changes.

3. Liver issues:

• Excessive fatigue.

• Loss of appetite.

• Right stomach pain.

• Urine that is dark or brown (tea color).

• Yellowing of the skin or whites of the eyes.

The most typical adverse effects of Diroximel fumarate are flushing, redness, rash, itching, nauseating feeling, regurgitation, loose stools, or indigestion. The most frequent side effects, particularly when therapy first begins, are flushing and gastrointestinal issues, but they may become less frequent with time.

Dietary considerations:

• Generally, eating or not eating is fine with taking Diroximel fumarate. But while taking the drug, some people could have gastrointestinal side effects, including nausea. In such circumstances, taking Diroximel fumarate with meals may help reduce discomfort.

• When taking Diroximel fumarate, patients should avoid eating meals or snacks high in fat or calories.

• If consumed with food, the meal or snack should include no more than 30 grams of fat and no more than 700 calories.

• Patients should be advised not to take Diroximel fumarate and alcohol at the same time.

Missed dose:

The correct procedure for missed doses of Diroximel fumarate is to take the medicine as soon as possible. The regular dosing schedule should be resumed instead of doubling up doses when an upcoming scheduled time to take medication is approaching. The practice of taking double doses when a medication is missed should be avoided entirely. The best way to achieve maximum treatment benefits for multiple sclerosis using Diroximel fumarate requires strict adherence to its recommended dosing plan.

Overdose:

Fast medical attention or a call to a local poison center becomes necessary when a Diroximel fumarate overdose is suspected. Excessive medication intake will enhance the likelihood of severe flushing and gastrointestinal symptoms, together with other adverse effects. The prevention of Diroximel fumarate overdose requires patients to follow healthcare prescriptions exactly. People who think they have taken an amount exceeding their prescribed dosage of Diroximel fumarate should immediately seek medical help.

Storage

• Maintaining the stability and effectiveness of Diroximel fumarate requires appropriate storage conditions.

• Storage recommendations include keeping the drug in its original container or packaging, at room temperature, and away from extreme heat or moisture.

• Store between 20 degrees Celsius and 25 degrees Celsius (68 degrees Fahrenheit and 77 degrees Fahrenheit); fluctuations are allowed between 15 degrees Celsius and 30 degrees Celsius (59 degrees Fahrenheit and 86 degrees Fahrenheit).

For Doctors:

Indication:

Multiple sclerosis (MS) relapsing types can be treated with Diroximel fumarate. The central nervous system is the main organ affected by this long-term autoimmune illness, which causes inflammation, demyelination, and neurological symptoms. As a disease-modifying treatment, Diroximel fumarate is recommended to lessen the likelihood of relapses and to delay the progression of MS-related impairment.

Dose:

Diroximel fumarate dosage is tailored to each patient's unique medical history and their individual response to the medication. The drug comes in tablet form with dosage levels ranging from 231 mg to 462 mg.

Dosing considerations:

Healthcare professionals take into account many criteria when choosing the proper treatment plan since these factors impact the dosage of Diroximel fumarate:

• Unique features of each patient: When determining the starting dose of Diroximel fumarate, the patient's overall health status, the severity of their MS, and any other disorders they may have are considered.

• Reaction to medication: A regular evaluation process determines how Diroximel fumarate affects the patient. The medication requirements need adjustment based on patient recovery, alongside observed adverse reactions.

• Tolerance: The primary requirement concerns how well the patient can handle the drug. Medical professionals should evaluate dosage adjustments to manage side effects while giving additional counseling to patients.

• Additional drugs and treatments: The researchers will evaluate potential drug interactions along with therapy effects to prevent both adverse side effects and reduced treatment efficacy.

• Patient compliance: For the drug to be effective, patients must follow the recommended dose regimen. Healthcare professionals may discuss any difficulties or worries about adherence during routine follow-up visits.

What Are the Pharmacological Aspects of Diroximel Fumarate?

Pharmacodynamics

Diroximel fumarate does not significantly prolong the QTc interval at a dosage twice the recommended amount.

Mechanism

The exact mechanism via which Diroximel fumarate treats multiple sclerosis is unknown. The nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway has been demonstrated to be activated by MMF, the active metabolite of Diroximel fumarate, in vitro and in vivo in humans and animals. A component of the physiological response to oxidative stress is the Nrf2 pathway. In vitro, MMF is an agonist of the nicotinic acid receptor.

Pharmacokinetics

• Absorption: The tablet form is used to administer Diroximel fumarate orally. After being taken orally, the prodrug enters the digestive system and is broken down to produce monomethyl fumarate.

• Distribution: Monomethyl fumarate, including the central nervous system, is found all over the body. The drug may now specifically target the inflammatory processes linked to multiple sclerosis because of this distribution.

• Metabolism: The liver converts Diroximel fumarate through a metabolic process to produce monomethyl fumarate, an active form with medicinal benefits.

• Excretion: Renal excretion is the primary method to remove the drug substance and its byproducts from the body. Veterinarians should pay attention to routine assessment of renal function across the treatment period.

Toxicity:

1. Clinical toxicity

• Flushing: Flushing is a typical clinical symptom that reduces comfort and adherence, existing on a scale between minor and severe. Healthcare professionals assess whether changes in dose strength or usage of symptomatic treatment should be implemented.

• Gastrointestinal symptoms: Diarrhea, together with stomach discomfort and nausea, serve as clinical indicators for this condition. Therapists address symptoms before potentially adjusting the medication dosage.

• Hematological effects: Medical staff need to track white blood cell counts, as the counts can mildly decrease, potentially leading to required adjustments in medication dosage.

• Allergic reaction: Dangerous allergic reactions to the medication may result in rashes, itching, or breathing problems, though these reactions occur exceptionally rarely. Such reactions need immediate medical attention for proper treatment. Medical experts require immediate treatment for these dangerous allergic reactions.

Clinical studies:

The purpose of Diroximel fumarate clinical trials has been to assess the medication's safety and effectiveness in treating relapse types of multiple sclerosis (MS). Evaluations of the medication's effects on relapse rates, the development of disabilities, and general patient well-being are frequently included in these studies. The information gathered from these clinical trial results is crucial in helping medical professionals decide whether to use Diroximel fumarate to treat multiple sclerosis.

What Are the Contraindications of Diroximel Fumarate?

Contraindications for diroximel fumarate:

The use of Diroximel Fumarate is prohibited in the following circumstances:

1. Severe allergic reaction: Diroximel fumarate should not be taken by anyone who has previously experienced a severe allergic reaction to the drug.

2. Use of concomitant Dimethyl Fumarate: Because Diroximel Fumarate and Dimethyl Fumarate (Tecfidera) share metabolization into the active Monomethyl fumarate, concurrent administration of these compounds is contraindicated.

3. Pregnancy: Diroximel fumarate should not be administered to pregnant women due to animal research showing harmful effects on the fetus.

4. Breastfeeding: It is contraindicated to use Diroximel Fumarate during breastfeeding since it is uncertain if it passes into breast milk.

5. Immunosuppressive or anti-neoplastic medicines: Since Diroximel Fumarate has not been investigated in conjunction with these medicines, concurrent usage should be used with caution, owing to the possibility of an increased infection risk.

Diroximel fumarate should be used with caution in the following situations:

1. Angioedema or anaphylaxis history.

2. Hepatic dysfunction.

3. A lymphopenic state.

4. Progressive Multifocal Leukoencephalopathy's (PML) history

Warnings and precautions:

• If anaphylaxis or edema develops, stop using Diroximel fumarate immediately and do not start again.

• If PML (Progressive Multifocal Leukoencephalopathy) occurs, withhold Diroximel fumarate at the first sign or symptom.

• Lymphopenia: Before starting Diroximel fumarate, and then every six to twelve months after that, obtain a complete blood count (CBC) that includes the lymphocyte count. Should lymphocyte counts below 0.5 × 109 per liter continue for over six months, consider stopping Diroximel fumarate.

• As clinically warranted, measure blood levels of total bilirubin, alkaline phosphatase, and aminotransferase before starting Diroximel fumarate and during therapy. If there is any suspicion of clinically severe liver damage caused by Diroximel fumarate, stop using the medication.

What Are the Drug Interactions of Diroximel Fumarate?

Like many other medications, Diroximel fumarate may interact with other medications, decreasing their efficacy or increasing the risk of adverse effects.

The following are some basic things to think about while using Diroximel fumarate with other medications:

• Fumarate dimethyl: Similarities exist between Diroximel fumarate and Fumarate dimethyl, another drug used to treat multiple sclerosis. The risk of adverse or additive effects may rise when Diroximel fumarate or other fumarates are used concurrently.

• Inducers and inhibitors of enzymes: Certain liver enzymes are involved in the metabolism of Diroximel fumarate. Medication stimulating or inhibiting these enzymes may affect the body's Diroximel fumarate levels and metabolism. Enzyme inducers such as Rifampin and enzyme inhibitors such as Fluoxetine are two examples.

• Drugs that impact the immune system: Due to the immune system modulation caused by Diroximel fumarate, using it in conjunction with other immunomodulating drugs or immunosuppressants may increase the risk of infections or harm the immune system.

• PPI or proton pump inhibitors: PPIs, frequently used to treat gastrointestinal disorders, may lessen Diroximel fumarate absorption. It is possible to minimize such interactions by taking Diroximel fumarate with or without meals.

Specific considerations:

• Pregnancy: It may be harmful to the fetus based on findings from animals. The developmental risk of Diroximel fumarate in pregnant women is not well-documented. Clinically relevant drug exposures were associated with adverse effects on embryofetal and offspring development (increased incidences of skeletal abnormalities, increased mortality, decreased body weights, and neurobehavioral impairment) when Diroximel fumarate was administered to animals during pregnancy or throughout pregnancy and lactation. The background risk of severe birth abnormalities and miscarriage in clinically recognized pregnancies is estimated to be two to four percent and 15 to 20 percent, respectively, in the general population of the United States. For the given group, the background risk of severe birth abnormalities and miscarriages is unknown.

• Pediatrics: The safety and effectiveness of treating pediatric patients are unknown.

• Senior usage: Not enough people 65 years of age and older were included in Diroximel fumarate clinical trials to ascertain whether their responses differed from those of younger patients.

Impairment of renal function: Modifying the dose for individuals with mild renal impairment is not necessary. In patients with moderate to severe renal impairment, the administration of Diroximel fumarate is not advised due to increased exposure to a significant metabolite, 2-Hydroxyethyl Succinimide (HES).